A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

NCT07017777 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections
Streptococcal Infections
Bacterial Infections

Interventions

BIOLOGICAL: PCV13i
BIOLOGICAL: Prevnar 13

Sponsor

CanSino Biologics Inc.